RxDoctor Payments Data

Heather Bastel

Nurse Practitioner · Paragould, ARNPI 1396712287

Payments from drug & device makers

$2,482in general payments, 2019–2025

Across 132 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$486
  • Novo Nordisk$393
  • Otsuka America Pharmaceutical, Inc.$379
  • AbbVie$278
  • Boehringer Ingelheim$191
  • GSK$175
  • plus $580 from 18 others

What the payments were for

  • Food & beverage$2,482100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,482 in reported general payments places this provider in the 80th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$61,751
Medicare patients
191
Services billed
2,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$80,170
OzempicSemaglutide61$78,225
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$46,605
Tresiba Flextouch U-200Insulin Degludec43$45,097
MounjaroTirzepatide32$37,125
RexultiBrexpiprazole22$36,567
EliquisApixaban47$35,121
JanuviaSitagliptin Phosphate25$34,279
FarxigaDapagliflozin Propanediol24$18,728
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$15,710
TrulicityDulaglutide15$14,502
Rufinamide12$13,190
Tresiba Flextouch U-100Insulin Degludec23$11,023
LinzessLinaclotide16$10,690
Dexlansoprazole DrDexlansoprazole48$10,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$191$80,17092 claims
Novo NordiskOzempic$393$78,22561 claims
GSKTrelegy Ellipta, Breo Ellipta$175$52,52651 claims
Lilly USA, LLCMounjaro, Trulicity$44$51,62747 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$486$38,84860 claims
Otsuka America Pharmaceutical, Inc.Rexulti$379$36,56722 claims
PfizerEliquis$15$35,12147 claims
MerckJanuvia$15$34,27925 claims
AbbVieLinzess$278$10,69016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Paragould

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →